[1]V.Kesic.Management of cervical cervical cancer.European Journal of Surgical [J].Oncology,2006,32(8):832-837. [2] Oliver Z,Kaled M,Yukio S,et al.Treatment patterns of FIGO Stage IB2 cervical cancer:a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy[J].Gynecol Oncol,2008,111(2):265-270. [3] 吴良芝,李春梅,刘雯雯,等.局部晚期宫颈癌新辅助化疗分子疗效研究[J]. 中国实验诊断学,2010,14(5):738-741. [4] RosePG.Locally advanced cervical cancer [J].Curr Opin Obstet Gynecol,2001,13(1):65-70. [5] Rob L,Halaska M,Robova H.Nerve sparing and individually tailored surgery for cervical cancer [J].Lancet Oncol,2010,11(3):292-301. [6] HornLC,Fischer U,Raptis G,et al.Hentschel.Tumor size is of prognostic value in surgically treated FIGO stage Ⅱcervical cancer [J].Gynecol Oncol,2007,107(2 ):310-315. [7] 严冬梅,宫颈癌术前新辅助化疗47例疗效观察[J].中华实用诊断与治疗杂志,2010,24(2):192-194. [8] Duenas-Gonzalez A,Cetina-Perez L,Onate-Ocana LF,et a1.Multimodal treatment of locally advanced cervical cancer[J].Arch Med Res,2005,36(2):129-135. [9] 王光,黄玲惠等,宫颈癌新辅助化疗疗效分析[J].中国妇产科临床杂志,2013,14(1):20-22. [10] Kim HS,Sardi JE,Katsumata N.Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer:An international collaborative meta-analysis,European Journal of Surgical Oncology,2013,39(2):115-124. [11] Park DC,Suh MJ,Yeo SG.Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer:long-term results[J].Int J Gynecol Cancer,2009,19(5):943-947. [12] 李超,局部晚期宫颈癌新辅助化疗疗效观察[J].肿瘤基础与临床,2011,24(4):334-335. [13] Vizza E,Pellegrino A,Milani R,et al.Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage IB2-IIB cervical cancer patients after neoadjuvant chemotherapy [J].Eur J Surg Oncol,2010,37(4):364-369. [14] Rose PG,Ali S,Watkins E,et al.Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin,cisplatin-based combination chemotherapy,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a Gynecologic Oncology Group Study[J].J Clin Oncol,2007,25(19):2804-2810. [15] Monk BJ,Tewari KS,Koh W-J.Multimodality therapy for locally advanced cervical carcinoma:state of the art and future directions[J].J Clin Oncol,2007,25:2952-2965. [16] 刘月玲,同步放化疗对中晚期宫颈癌患者的临床治疗效果[J].中国实用医药,2012,7(2),53-54. [17] Eifel PJ.Chemoradiotherapy in the treatment of cervical cancer[J].Semin Radiat,2006,16(3):177. [18] Kantardzie N.Concurrent chemoradiation for cervical cancer:results offive randomized trials [J].Med Arh,2010,64(6):368. [19] 魏伟锋,子宫动脉灌注新辅助化疗在II期宫颈癌治疗中的可行性及[J].临床合理用药杂志,2013,6(2):84. [20] 熊琼英,广怡,刘成 宫颈癌新辅助化疗疗法不同途径的疗效评价[J].现代妇产科进展,2012,21(1):55-57. [21] Gadducci A,Fabrini MG,Perrone F,et al.Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach [J].Anticancer Res,2010,30(9):3731-3735. [22] ChenH,Liang C,Zhang L,et al.Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced(stage ⅠB2 to ⅡB) cervical cancer:randomized study[J].Gynecol Oncol,2008,110(3):308-315. [23] Watari H,Kanuma T,Ohta Y,et al.Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin based neoadjuvant chemotherapy and radical hysterectomy [J].Pathol Oncol Res,2010,16(3):345- 352. [24] Park JS,Jeon EK,Chun SH,et al.ERCC1(excision repair cross co mplementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer [J].Gynecol Oncol,2011,120(2):275-279. [25] McCormack M,Ledermann JA,Hall C raggs MA,et al.A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer [J].British Journal of Cancer,2013,108(12):2464-2469. |